Evidence map›Paper›PMID 34606835›Full record

ArticleEuropean journal of pharmacology2021

Clopidogrel treatment inhibits P2Y

Dawn S Kuszynski, Barbara D Christian, Anne M Dorrance, D Adam Lauver

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. P2YBiomedicines · 2025
    Article
  2. Pleiotropic effects of clopidogrel.Purinergic signalling · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dawn S KuszynskiDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA; Institute of Integrative Toxicology, Michigan State University, East Lansing, MI, USA.
Barbara D ChristianDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Anne M DorranceDepartment of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
D Adam LauverDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA. Electronic address: lauverda@msu.edu.
Michigan State University · US

Funding

Novel ClopNPT for the treatment of acute coronary syndromeR43HL139380 · NHLBI · DIAPIN THERAPEUTICS, LLC · PI MA, ZHONGMIN ALEX · 2017 to 2017
$225k
The Vascular Effects of Clopidogrel MetabolitesF31HL154613 · NHLBI · MICHIGAN STATE UNIVERSITY · PI KUSZYNSKI, DAWN · 2020 to 2021
$92k
NHLBI NIH HHS F31 HL154613NHLBI NIH HHS R43 HL139380
6 · The paper itself

Abstract

Clopidogrel is an effective purinergic 2Y

Indexed as

ClopidogrelMiddle Cerebral ArteryPlatelet AggregationPurinergic P2Y Receptor AntagonistsVasoconstrictionAdenosine DiphosphateAnimalsMalePlatelet Aggregation InhibitorsRabbitsReceptors, Purinergic P2Y12Receptors, Purinergic P2Y2Adenosine DiphosphateClopidogrelPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Receptors, Purinergic P2Y2ClopidogrelPlateletsPressure myographyPurinergic receptorsPurinoreceptor agonistsRabbits

Identifiers

PMID34606835
PMCPMC8577565
OpenAlexW3203584165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.